SI3515910T1 - Derivati 5-(2-(piridin-2-ilamino)-1,3-tiazol-5-il)-2,3-dihidro-1H-izoindol-1- ona in njihova uporaba kot dvojni inhibitorji fosfatidilinozitol 3- kinaze delta in gama - Google Patents

Derivati 5-(2-(piridin-2-ilamino)-1,3-tiazol-5-il)-2,3-dihidro-1H-izoindol-1- ona in njihova uporaba kot dvojni inhibitorji fosfatidilinozitol 3- kinaze delta in gama

Info

Publication number: SI3515910T1
Authority: SI; Slovenia
Prior art keywords: isoindol; phosphatidylinositol; ylamino; thiazol; pyridin
Prior art date: 2016-09-22

Application number

SI201730357T

Other languages

English (en)

Inventor

Matthew Perry

Konstantinos Karabelas

Mickael Mogemark

Peter Bold

Christian Tyrchan

Antonios Nikitidis

Jens Petersen

Ulf Borjesson

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-09-22

Filing date

2017-09-21

Publication date

2020-09-30

2017-09-21 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2020-09-30 Publication of SI3515910T1 publication Critical patent/SI3515910T1/sl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Pulmonology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

SI201730357T 2016-09-22 2017-09-21 Derivati 5-(2-(piridin-2-ilamino)-1,3-tiazol-5-il)-2,3-dihidro-1H-izoindol-1- ona in njihova uporaba kot dvojni inhibitorji fosfatidilinozitol 3- kinaze delta in gama SI3515910T1 (sl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201662398006P	2016-09-22	2016-09-22
EP17772381.4A EP3515910B1 (en)	2016-09-22	2017-09-21	5-[2-(pyridin-2-ylamino)-1,3-thiazol-5-yl]-2,3-dihydro-1h-isoindol-1-one derivatives and their use as dual inhibitors of phosphatidylinositol 3-kinase delta & gamma
PCT/EP2017/073916 WO2018055040A1 (en)	2016-09-22	2017-09-21	5-[2-(pyridin-2-ylamino)-1,3-thiazol-5-yl]-2,3-dihydro-1 h-isoindol-1 -one derivatives and their use as dual inhibitors of phosphatidylinositol 3-kinase delta & gamma

Publications (1)

Publication Number	Publication Date
SI3515910T1 true SI3515910T1 (sl)	2020-09-30

Family

ID=59966739

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SI201730357T SI3515910T1 (sl)	2016-09-22	2017-09-21	Derivati 5-(2-(piridin-2-ilamino)-1,3-tiazol-5-il)-2,3-dihidro-1H-izoindol-1- ona in njihova uporaba kot dvojni inhibitorji fosfatidilinozitol 3- kinaze delta in gama

Country Status (36)

Country	Link
US (2)	US10961236B2 (sl)
EP (1)	EP3515910B1 (sl)
JP (1)	JP6765516B2 (sl)
KR (1)	KR102226098B1 (sl)
CN (1)	CN109715623A (sl)
AR (1)	AR109706A1 (sl)
AU (1)	AU2017331940B2 (sl)
BR (1)	BR112019004719A2 (sl)
CA (1)	CA3036304A1 (sl)
CL (1)	CL2019000707A1 (sl)
CO (1)	CO2019003440A2 (sl)
CR (1)	CR20190200A (sl)
CY (1)	CY1123346T1 (sl)
DK (1)	DK3515910T3 (sl)
DO (1)	DOP2019000073A (sl)
EA (1)	EA036176B1 (sl)
EC (1)	ECSP19027780A (sl)
ES (1)	ES2818583T3 (sl)
HR (1)	HRP20201175T1 (sl)
HU (1)	HUE051634T2 (sl)
IL (1)	IL265298B (sl)
JO (1)	JOP20190052A1 (sl)
LT (1)	LT3515910T (sl)
MA (1)	MA46268B1 (sl)
MX (2)	MX381898B (sl)
PE (1)	PE20190909A1 (sl)
PH (1)	PH12019500615A1 (sl)
PL (1)	PL3515910T3 (sl)
PT (1)	PT3515910T (sl)
RS (1)	RS60764B1 (sl)
SI (1)	SI3515910T1 (sl)
SM (1)	SMT202000481T1 (sl)
SV (1)	SV2019005857A (sl)
TW (1)	TW201813967A (sl)
UA (1)	UA123558C2 (sl)
WO (1)	WO2018055040A1 (sl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US11078204B2 (en)	2018-11-13	2021-08-03	Incyte Corporation	Heterocyclic derivatives as PI3K inhibitors
WO2020102150A1 (en)	2018-11-13	2020-05-22	Incyte Corporation	Heterocyclic derivatives as pi3k inhibitors
WO2020102216A1 (en)	2018-11-13	2020-05-22	Incyte Corporation	Substituted heterocyclic derivatives as pi3k inhibitors
CN114025756B (zh) *	2019-04-10	2022-09-27	南京征祥医药有限公司	磷脂酰肌醇3-激酶抑制剂
CN114206332B (zh)	2019-06-04	2024-08-23	艾库斯生物科学有限公司	2,3,5-三取代吡唑并[1,5-a]嘧啶化合物
WO2022017371A1 (zh) *	2020-07-21	2022-01-27	中国医药研究开发中心有限公司	具有磷脂酰肌醇3-激酶δ和γ的双重抑制剂活性的杂环化合物及其医药用途
WO2022023456A1 (en)	2020-07-29	2022-02-03	Astrazeneca Ab	Pharmaceutical compositions comprising nano embedded microparticles and methods of use
CN116813608B (zh) *	2023-06-08	2024-03-22	英矽智能科技(上海)有限公司	噻唑类化合物及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK1347971T3 (da) *	2000-12-21	2006-05-15	Bristol Myers Squibb Co	Thiazolylinhibitorer af tyrosinkinaser fra Tec-familien
GB0305152D0 (en) *	2003-03-06	2003-04-09	Novartis Ag	Organic compounds
GB0320197D0 (en) *	2003-08-28	2003-10-01	Novartis Ag	Organic compounds
JP2008543754A (ja) *	2005-06-09	2008-12-04	メルクエンドカムパニーインコーポレーテッド	チェックポイントキナーゼの阻害剤
EP2183232B1 (en) *	2007-08-02	2013-03-06	Amgen, Inc	Pi3 kinase modulators and methods of use
UY33337A (es)	2010-10-18	2011-10-31	Respivert Ltd	DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
WO2013012918A1 (en)	2011-07-19	2013-01-24	Infinity Pharmaceuticals Inc.	Heterocyclic compounds and uses thereof
WO2013012915A1 (en)	2011-07-19	2013-01-24	Infinity Pharmaceuticals Inc.	Heterocyclic compounds and uses thereof
AR091790A1 (es)	2011-08-29	2015-03-04	Infinity Pharmaceuticals Inc	Derivados de isoquinolin-1-ona y sus usos
WO2013052699A2 (en)	2011-10-04	2013-04-11	Gilead Calistoga Llc	Novel quinoxaline inhibitors of pi3k
UA119315C2 (uk)	2012-07-03	2019-06-10	Гіліад Фармассет Елелсі	Інгібітори вірусу гепатиту с
UY35332A (es)	2013-02-15	2014-11-28	Almirall Sa	Derivados de pirrolotriazina como inhibidores de pi3k
US11352359B2 (en)	2013-07-02	2022-06-07	Rhizen Pharmaceuticals Ag	PI3K protein kinase inhibitors
UY35675A (es)	2013-07-24	2015-02-27	Novartis Ag	Derivados sustituidos de quinazolin-4-ona
DK3160968T3 (en)	2014-06-27	2019-02-18	Rhizen Pharmaceuticals S A	SUBSTITUTED CHROMINE DERIVATIVES AS SELECTIVE DOUBLE INHIBITORS OF PI3 DELTA AND GAMMA PROTEIN KINASES

2017
- 2017-06-16 JO JOP/2019/0052A patent/JOP20190052A1/ar unknown
- 2017-09-21 HU HUE17772381A patent/HUE051634T2/hu unknown
- 2017-09-21 UA UAA201903648A patent/UA123558C2/uk unknown
- 2017-09-21 BR BR112019004719A patent/BR112019004719A2/pt not_active IP Right Cessation
- 2017-09-21 MX MX2019003194A patent/MX381898B/es unknown
- 2017-09-21 MA MA46268A patent/MA46268B1/fr unknown
- 2017-09-21 CN CN201780057289.2A patent/CN109715623A/zh active Pending
- 2017-09-21 RS RS20201077A patent/RS60764B1/sr unknown
- 2017-09-21 PE PE2019000702A patent/PE20190909A1/es unknown
- 2017-09-21 EP EP17772381.4A patent/EP3515910B1/en active Active
- 2017-09-21 EA EA201990664A patent/EA036176B1/ru not_active IP Right Cessation
- 2017-09-21 US US16/332,620 patent/US10961236B2/en not_active Expired - Fee Related
- 2017-09-21 KR KR1020197010973A patent/KR102226098B1/ko not_active Expired - Fee Related
- 2017-09-21 HR HRP20201175TT patent/HRP20201175T1/hr unknown
- 2017-09-21 CR CR20190200A patent/CR20190200A/es unknown
- 2017-09-21 SM SM20200481T patent/SMT202000481T1/it unknown
- 2017-09-21 WO PCT/EP2017/073916 patent/WO2018055040A1/en not_active Ceased
- 2017-09-21 DK DK17772381.4T patent/DK3515910T3/da active
- 2017-09-21 SI SI201730357T patent/SI3515910T1/sl unknown
- 2017-09-21 AU AU2017331940A patent/AU2017331940B2/en not_active Ceased
- 2017-09-21 TW TW106132359A patent/TW201813967A/zh unknown
- 2017-09-21 PL PL17772381.4T patent/PL3515910T3/pl unknown
- 2017-09-21 JP JP2019515477A patent/JP6765516B2/ja not_active Expired - Fee Related
- 2017-09-21 CA CA3036304A patent/CA3036304A1/en not_active Abandoned
- 2017-09-21 LT LTEP17772381.4T patent/LT3515910T/lt unknown
- 2017-09-21 ES ES17772381T patent/ES2818583T3/es active Active
- 2017-09-21 PT PT177723814T patent/PT3515910T/pt unknown
- 2017-09-22 AR ARP170102631A patent/AR109706A1/es unknown
2019
- 2019-03-11 IL IL265298A patent/IL265298B/en active IP Right Grant
- 2019-03-19 CL CL2019000707A patent/CL2019000707A1/es unknown
- 2019-03-20 DO DO2019000073A patent/DOP2019000073A/es unknown
- 2019-03-20 MX MX2021004748A patent/MX2021004748A/es unknown
- 2019-03-21 PH PH12019500615A patent/PH12019500615A1/en unknown
- 2019-03-22 SV SV2019005857A patent/SV2019005857A/es unknown
- 2019-04-08 CO CONC2019/0003440A patent/CO2019003440A2/es unknown
- 2019-04-17 EC ECSENADI201927780A patent/ECSP19027780A/es unknown
2020
- 2020-09-09 CY CY20201100856T patent/CY1123346T1/el unknown
2021
- 2021-02-11 US US17/173,826 patent/US20210246130A1/en not_active Abandoned

Also Published As

Publication number	Publication date
ES2818583T3 (es)	2021-04-13
EA036176B1 (ru)	2020-10-09
EA201990664A1 (ru)	2019-08-30
BR112019004719A2 (pt)	2019-05-28
EP3515910B1 (en)	2020-07-15
AU2017331940A1 (en)	2019-05-02
KR102226098B1 (ko)	2021-03-09
PE20190909A1 (es)	2019-06-26
CA3036304A1 (en)	2018-03-29
US10961236B2 (en)	2021-03-30
HRP20201175T1 (hr)	2020-11-13
LT3515910T (lt)	2020-10-12
KR20190049867A (ko)	2019-05-09
CR20190200A (es)	2019-06-07
US20210246130A1 (en)	2021-08-12
CY1123346T1 (el)	2022-03-24
MX381898B (es)	2025-03-13
SMT202000481T1 (it)	2020-11-10
EP3515910A1 (en)	2019-07-31
CL2019000707A1 (es)	2019-05-31
PH12019500615A1 (en)	2019-06-03
JP2019529445A (ja)	2019-10-17
IL265298A (en)	2019-05-30
JP6765516B2 (ja)	2020-10-07
MA46268A (fr)	2019-07-31
MA46268B1 (fr)	2020-08-31
AU2017331940B2 (en)	2020-03-12
DOP2019000073A (es)	2019-04-15
SV2019005857A (es)	2019-05-06
CO2019003440A2 (es)	2019-04-12
IL265298B (en)	2020-09-30
US20200308164A1 (en)	2020-10-01
UA123558C2 (uk)	2021-04-21
DK3515910T3 (da)	2020-08-31
ECSP19027780A (es)	2019-04-30
HUE051634T2 (hu)	2021-03-01
MX2021004748A (es)	2021-06-08
RS60764B1 (sr)	2020-10-30
PL3515910T3 (pl)	2021-02-22
CN109715623A (zh)	2019-05-03
PT3515910T (pt)	2020-09-16
WO2018055040A1 (en)	2018-03-29
AR109706A1 (es)	2019-01-16
TW201813967A (zh)	2018-04-16
MX2019003194A (es)	2019-06-17
JOP20190052A1 (ar)	2019-03-21

Publication	Publication Date	Title
SI3515910T1 (sl)	2020-09-30	Derivati 5-(2-(piridin-2-ilamino)-1,3-tiazol-5-il)-2,3-dihidro-1H-izoindol-1- ona in njihova uporaba kot dvojni inhibitorji fosfatidilinozitol 3- kinaze delta in gama
IL276333B (en)	2021-07-29	Cyclic sulfamoylarylamide history and their use as drugs to treat hepatitis b
EP3672973A4 (en)	2021-05-26	HETEROCYCLIC COMPOUNDS USED AS KINASE INHIBITORS, COMPOSITIONS INCLUDING THE HETEROCYCLIC COMPOUND, AND METHODS OF USE THEREOF
SG11202011513RA (en)	2020-12-30	Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
ZA201700652B (en)	2019-12-18	2-h-indazole derivatives as cyclin-dependent kinase (cdk) inhibitors and therapeutic uses thereof
PL3805233T3 (pl)	2024-06-10	ENANCJOMERY (R) I (S) (S)-N-(5-(3-hydroksypirolidyn-1-ylo)-2-morfolinooksazolo[4,5-b]pirydyn-6-ylo)-2-(2-metylopirydyn-4-ylo)oksazolo-4-karboksyamidu jako inhibitory IRAK4 do leczenia nowotworu złośliwego
HUE060152T2 (hu)	2023-02-28	4-(3H-indol-5-il)-N-(piridin-2-il)pirimidin-2-amin-származékok mint proteinkináz inhibitorok, elõállítási eljárásuk és gyógyászati alkalmazásuk
IL252981B (en)	2019-07-31	History of 5-[(piperazine-1-yl)-3-oxo-propyl]-imidazolidine-4,2-dione as adamts inhibitors for the treatment of osteoarthritis
EP3697791A4 (en)	2021-06-16	HETEROCYCLIC COMPOUNDS, COMPOSITIONS INCLUDING THE HETEROCYCLIC COMPOUND, AND METHODS OF USE THEREOF
EP3266774A4 (en)	2018-08-08	Substituted pyrimidine compounds as phosphatidylinositol 3-kinase delta inhibitor and use thereof
IL267829B (en)	2022-02-01	History of new amino-imidazopyridines as Janus kinase inhibitors and their pharmaceutical use
PL3154939T3 (pl)	2020-03-31	Sposób syntezy 2-(2,5-dimetylo-1h-pirol-1-ilo)-1,3-propanodiolu i jego podstawionych pochodnych
SG11201610745XA (en)	2017-01-27	Substituted chromene derivatives as selective dual inhibitors of pi3 delta and gamma protein kinases
LT3212644T (lt)	2021-06-25	2-(1,2,4-triazol-3-ilsulfanil)-n-1,3,4-tiadiazol-2-ilacetamido dariniai, kurie yra naudotini diabeto gydymui
SI3019497T1 (sl)	2017-07-31	Nova sol 3-((3-((4-(4-morfolinilmetil)-1h-pirol-2-il)metilen)-2-okso- 2,3-dihidro-1h-indol-5-il)metil)-1,3-tiazolidin-2,4-diona, njen sestavek in formulacije, ki jo vsebujejo
HK40091939A (zh)	2023-12-15	作为ehmt2抑制剂的胺取代的杂环化合物及其使用方法
PH12017500124B1 (en)	2017-05-29	Azole benzene derivative and crystalline form thereof
HK40012933A (en)	2020-07-31	Heterocyclic compounds as inhibitors of ras and methods of use thereof
HK40036207A (en)	2021-05-21	Amine-substituted heterocyclic compounds as ehmt2 inhibitors, salts thereof, and methods of synthesis thereof
BR112016022974A2 (pt)	2017-12-26	derivados de 2,4-tiazolidinadiona no tratamento de distúrbios do sistema nervoso central
HK1240918A1 (en)	2018-06-01	2-h-indazole derivatives as cyclin-dependent kinase (cdk) inhibitors and therapeutic uses thereof
HK1241865A1 (en)	2018-06-15	2-[bis(4-fluorophenyl)methyl]-2,7-diazaspiro[4.5]decan-10-one derivatives and related compounds as inhibitors of the human dopamine-active-transporter (dat) protein for the treatment of e.g. attention deficit disorder (add)